ORGO Organogenesis Holdings Inc

Price (delayed)

$4.89

Market cap

$620.33M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.14

Enterprise value

$587.42M

Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis's ...

Highlights

ORGO's debt has dropped by 63% year-on-year and by 4.3% since the previous quarter

The net income has soared by 50% YoY and by 48% from the previous quarter

The quick ratio has grown by 29% year-on-year but it has declined by 10% since the previous quarter

The EPS is up by 18% since the previous quarter but it has declined by 8% year-on-year

ORGO's equity is down by 11% YoY and by 4% QoQ

Organogenesis Holdings's gross profit has decreased by 8% QoQ and by 4.9% YoY

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Website: http://www.organogenesis.com

Peers: OPK

Key stats

What are the main financial stats of ORGO

Market

Shares outstanding

126.86M

Market cap

$620.33M

Enterprise value

$587.42M

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

2.66

Price to sales (P/S)

1.44

EV/EBIT

N/A

EV/EBITDA

194.9

EV/Sales

1.37

Earnings

Revenue

$429.53M

Gross profit

$320.33M

Operating income

-$22.83M

Net income

-$8.23M

EBIT

-$22.76M

EBITDA

$3.01M

Free cash flow

-$46.37M

Per share

EPS

-$0.14

EPS diluted

-$0.14

Free cash flow per share

-$0.37

Book value per share

$1.84

Revenue per share

$3.39

TBVPS

$3.32

Balance sheet

Total assets

$461.13M

Total liabilities

$99.91M

Debt

$40.82M

Equity

$233.24M

Working capital

$194.38M

Liquidity

Debt to equity

0.17

Current ratio

3.95

Quick ratio

2.95

Net debt/EBITDA

-10.92

Margins

EBITDA margin

0.7%

Gross margin

74.6%

Net margin

-1.9%

Operating margin

-5.3%

Efficiency

Return on assets

-3.3%

Return on equity

-6.1%

Return on invested capital

-7.3%

Return on capital employed

-5.8%

Return on sales

-5.3%

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

ORGO stock price

How has the Organogenesis Holdings stock price performed over time

Intraday

5.96%

1 week

7.95%

1 month

13.72%

1 year

102.07%

YTD

52.81%

QTD

33.61%

Financial performance

How have Organogenesis Holdings's revenue and profit performed over time

Revenue

$429.53M

Gross profit

$320.33M

Operating income

-$22.83M

Net income

-$8.23M

Gross margin

74.6%

Net margin

-1.9%

Organogenesis Holdings's operating margin has shrunk by 121% YoY

Organogenesis Holdings's operating income has plunged by 109% YoY but it has increased by 5% from the previous quarter

The net income has soared by 50% YoY and by 48% from the previous quarter

ORGO's net margin is up by 49% year-on-year and by 46% since the previous quarter

Price vs fundamentals

How does ORGO's price correlate with its fundamentals

Growth

What is Organogenesis Holdings's growth rate over time

Valuation

What is Organogenesis Holdings stock price valuation

ORGO P/E details

P/E

N/A

P/B

2.66

P/S

1.44

EV/EBIT

N/A

EV/EBITDA

194.9

EV/Sales

1.37

The EPS is up by 18% since the previous quarter but it has declined by 8% year-on-year

The P/B is 48% above the last 4 quarters average of 1.8 but 32% below the 5-year quarterly average of 3.9

ORGO's equity is down by 11% YoY and by 4% QoQ

ORGO's P/S is 44% above its last 4 quarters average of 1.0 but 20% below its 5-year quarterly average of 1.8

The company's revenue fell by 6% QoQ and by 4.2% YoY

Efficiency

How efficient is Organogenesis Holdings business performance

The return on invested capital has dropped by 135% year-on-year but it is up by 5% since the previous quarter

The return on sales has dropped by 121% year-on-year

The ROA has grown by 25% from the previous quarter and by 8% YoY

Organogenesis Holdings's return on equity has increased by 22% QoQ

Dividends

What is ORGO's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for ORGO.

Financial health

How did Organogenesis Holdings financials performed over time

The current ratio has grown by 45% YoY but it has contracted by 4.1% from the previous quarter

Organogenesis Holdings's total liabilities has decreased by 44% YoY

ORGO's debt is 83% smaller than its equity

ORGO's debt has dropped by 63% year-on-year and by 4.3% since the previous quarter

The debt to equity has dropped by 60% year-on-year and by 6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.